Initiate the CID-103 Phase 1 study in multiple myeloma patients
Delivered after the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 16 Feb 2021
- Due
- 31 Mar 2021
- Delivered
- June 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“remain on track to initiate our CID-103 study in multiple myeloma patients in the first quarter”
What we found
Evidence strength A What the grades mean
The company committed to initiating the CID-103 study in Q1 2021, but later filings confirm the first patient was enrolled in June 2021, missing the original deadline.
-
A CASI Pharmaceuticals, Inc. 10-Q filed 2021-08-12
“The Company achieved in June 2021 the First-Patient-In (FPI) in the Phase 1 dose escalation and expansion study of CID-103” ✓ confirmed on the page
-
A CASI Pharmaceuticals, Inc. 10-Q filed 2021-08-12
“The COVID-19 pandemic impacted our targeted start time of our CID-103 trial” ✓ confirmed on the page
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- CID-103 Phase 1 study
- Language
- Firm (“will”, “on track to”)
- In the company’s control
- High
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you CASI Pharmaceuticals, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C895051-023804 · Corrections policy